Literature DB >> 6921203

Formation and structure of human Hageman factor fragments.

J T Dunn, A P Kaplan.   

Abstract

Autodigestion of activated Hageman factor (HFa) yields a 40,000-mol wt activated enzyme as well as Hageman factor fragment (HFf); HFf consists of two molecular weight species of 28,500 and 30,000. We have investigated the structure of these active fragments and demonstrate that upon reduction, each possesses a heavy chain of 28,000. The associated light chains were identified by subjecting iodinated proteins to two-dimensional slab gel electrophoresis in which the second dimension is run reduced. The 40,000-dalton enzyme has a light chain of 15,000, the 30,000-dalton form of HFf has a light chain of 2,000 and we have suggestive evidence of a light chain associated with the 28,500-dalton form of HFf (putative mol wt approximately 500). We also demonstrate that the 30,000-dalton form of HFf precedes the 28,500 form. These data indicate that digestion of native HF to form HFa precedes cleavages that fragment the molecule and diminish its molecular weight. The 28,500-dalton light chain of HFa becomes the heavy chain of each of the fragmentation products while cleavage at different points along the heavy chain of HFa determines which fragments will be produced. In contrast to autoactivation, kallikrein digestion of HFa yields primarily HFf; however, the 40,000-dalton enzyme may be seen when prekallikrein-deficient (Fletcher trait) plasma is activated.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6921203      PMCID: PMC370265          DOI: 10.1172/jci110656

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  16 in total

1.  Characterization of bovine factor XIIa (activated Hageman factor).

Authors:  K Fujikawa; K Kurachi; E W Davie
Journal:  Biochemistry       Date:  1977-09-20       Impact factor: 3.162

2.  Three-dimensional Fourier synthesis of tosyl-elastase at 3.5 å resolution.

Authors:  H C Watson; D M Shotton; J M Cox; H Muirhead
Journal:  Nature       Date:  1970-02-28       Impact factor: 49.962

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  A pre-albumin activator of prekallikrein.

Authors:  A P Kaplan; K F Austen
Journal:  J Immunol       Date:  1970-10       Impact factor: 5.422

5.  Structure of crystalline -chymotrypsin. II. A preliminary report including a hypothesis for the activation mechanism.

Authors:  P B Sigler; D M Blow; B W Matthews; R Henderson
Journal:  J Mol Biol       Date:  1968-07-14       Impact factor: 5.469

6.  The binding and cleavage characteristics of human Hageman factor during contact activation. A comparison of normal plasma with plasmas deficient in factor XI, prekallikrein, or high molecular weight kininogen.

Authors:  S D Revak; C G Cochrane; J H Griffin
Journal:  J Clin Invest       Date:  1977-06       Impact factor: 14.808

7.  Hageman factor substrates. Human plasma prekallikrein: mechanism of activation by Hageman factor and participation in hageman factor-dependent fibrinolysis.

Authors:  R Mandle; A P Kaplan
Journal:  J Biol Chem       Date:  1977-09-10       Impact factor: 5.157

8.  Activation of Hageman factor in solid and fluid phases. A critical role of kallikrein.

Authors:  C G Cochrane; S D Revak; K D Wuepper
Journal:  J Exp Med       Date:  1973-12-01       Impact factor: 14.307

9.  A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin.

Authors:  A P Kaplan; K F Austen
Journal:  J Exp Med       Date:  1971-04-01       Impact factor: 14.307

10.  Surface and fluid phase activities of two forms of activated Hageman factor produced during contact activation of plasma.

Authors:  S D Revak; C G Cochrane; B N Bouma; J H Griffin
Journal:  J Exp Med       Date:  1978-03-01       Impact factor: 14.307

View more
  9 in total

1.  Amidolytic, procoagulant, and activation-suppressing proteins produced by contact activation of blood factor XII in buffer solution.

Authors:  Avantika Golas; Chyi-Huey Joshua Yeh; Christopher A Siedlecki; Erwin A Vogler
Journal:  Biomaterials       Date:  2011-09-28       Impact factor: 12.479

Review 2.  Complement, Kinins, and Hereditary Angioedema: Mechanisms of Plasma Instability when C1 Inhibitor is Absent.

Authors:  Allen P Kaplan; Kusumam Joseph
Journal:  Clin Rev Allergy Immunol       Date:  2016-10       Impact factor: 8.667

Review 3.  Bradykinin formation. Plasma and tissue pathways and cellular interactions.

Authors:  A P Kaplan; K Joseph; Y Shibayama; Y Nakazawa; B Ghebrehiwet; S Reddigari; M Silverberg
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

4.  Inactivation of factor XII active fragment in normal plasma. Predominant role of C-1-inhibitor.

Authors:  A de Agostini; H R Lijnen; R A Pixley; R W Colman; M Schapira
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

5.  The IgE-dependent release of a Hageman factor cleaving factor from human lung.

Authors:  H L Meier; B Flowers; M Silverberg; A P Kaplan; H H Newball
Journal:  Am J Pathol       Date:  1986-04       Impact factor: 4.307

6.  Ir-CPI, a coagulation contact phase inhibitor from the tick Ixodes ricinus, inhibits thrombus formation without impairing hemostasis.

Authors:  Yves Decrem; Géraldine Rath; Virginie Blasioli; Philippe Cauchie; Séverine Robert; Jérôme Beaufays; Jean-Marie Frère; Olivier Feron; Jean-Michel Dogné; Chantal Dessy; Luc Vanhamme; Edmond Godfroid
Journal:  J Exp Med       Date:  2009-10-05       Impact factor: 14.307

Review 7.  Blood Clotting and the Pathogenesis of Types I and II Hereditary Angioedema.

Authors:  Steven de Maat; Kusumam Joseph; Coen Maas; Allen P Kaplan
Journal:  Clin Rev Allergy Immunol       Date:  2021-05-06       Impact factor: 8.667

8.  Hereditary angioedema attacks resolve faster and are shorter after early icatibant treatment.

Authors:  Marcus Maurer; Werner Aberer; Laurence Bouillet; Teresa Caballero; Vincent Fabien; Gisèle Kanny; Allen Kaplan; Hilary Longhurst; Andrea Zanichelli
Journal:  PLoS One       Date:  2013-02-04       Impact factor: 3.240

Review 9.  The Story of Angioedema: from Quincke to Bradykinin.

Authors:  Avner Reshef; Mona Kidon; Iris Leibovich
Journal:  Clin Rev Allergy Immunol       Date:  2016-10       Impact factor: 10.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.